SuperworthPersonalis PSNL
- Market cap
- $1.7B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 24.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $69.7M
- −13% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −6.0%
Personalis trades at 24.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $69.7M over the last twelve months, down 13% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $18.2M+23% | $19.7M+18% | $19.5M+4% | $22.6M+35% | $25.7M+41% | $16.8M−15% | $20.6M+6% | $17.2M−24% | $14.5M−44% | $17.3M+3% | $15.5M−25% | $22.4M+30% | |
| Cost of revenue | $14.8M+19% | $14.5M+0% | $14M−1% | $14.5M+22% | $17M+15% | $12.3M−15% | $13.4M−5% | $12.4M−14% | $12.6M−26% | $15.4M+26% | $15.2M+13% | $17.6M+42% |
| Gross profit | $3.5M+40% | $5.2M+125% | $5.5M+16% | $8M+68% | $8.7M+151% | $4.5M−13% | $7.2M+31% | $4.8M−41% | $1.9M−78% | $1.9M−58% | $281K−96% | $4.7M−0% |
| R&D | $16.7M+12% | $13.6M−18% | $12.8M−23% | $13M−27% | $11.7M−30% | $11.5M−16% | $12.6M−1% | $12.4M−4% | $12.2M+4% | $13.1M+14% | $14.5M+15% | $16.3M+32% |
| SG&A | $12M−19% | $11.5M−35% | $11.6M−18% | $12M−1% | $11.4M−4% | $11.2M−3% | $12.3M+6% | $14.2M+18% | $13M+14% | $14.1M+26% | $17.9M+46% | $22M+55% |
| −$30.8M+13% | −$24M−25% | −$18.9M−37% | −$16.9M−33% | −$14.4M−53% | −$18.1M−24% | −$17.7M−6% | −$21.8M+29% | −$23.3M+62% | −$25.3M+40% | −$32.2M+82% | −$33.6M+54% | |
| Interest expense | $15K−67% | $9K−81% | $9K−81% | $9K−77% | $7K−53% | −$1K | $28K+211% | $48K+433% | $64K+814% | $65K | $47K+68% | $37K−23% |
| Pre-tax income | −$29.1M+10% | −$26.6M−14% | −$13M−55% | −$12.8M−47% | −$39.1M+35% | −$16.4M−38% | −$15.7M+22% | −$20.1M+57% | −$21.6M−45% | −$23.8M+45% | −$30M+91% | −$31.7M+58% |
| $28K+155% | $5K−38% | $7K−50% | $4K−89% | $3K−89% | $4K−20% | $7K+0% | $2K−50% | $3K+0% | $9K+125% | $16K+129% | $5K+150% | |
| Net income | −$29.1M+10% | −$26.6M−14% | −$13M−55% | −$12.8M−47% | −$39.1M+34% | −$16.4M−38% | −$15.8M+22% | −$20.1M+57% | −$21.7M−45% | −$23.8M+45% | −$30M+91% | −$31.7M+58% |
| −$0.60+3% | −$0.54−19% | −$0.26−57% | −$0.24−52% | −$0.64+7% | −$0.23−57% | −$0.18−31% | −$0.23−4% | −$0.24−63% | −$0.26+13% | −$0.29+61% | −$0.30+30% | |
| 48.7M+6% | 49.6M+7% | 50.7M+8% | 52.4M+10% | 61.1M+25% | 72.8M+47% | 87.5M+73% | 88.5M+69% | 88.7M+45% | 92.2M+27% | 104.2M+19% | 105.4M+19% |
Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them. 32 periods, Q2 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Income tax: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 9 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Personalis' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PSNLPersonalis | $1.7B | n/m | n/a | 24.3× | −13% | n/m | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | 9.1× | +85% | 10.6% | |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | 3.8× | +1% | 8.6% | |
| Peer median | $5.1B | 44.8× | 35.1× | 6.9× | +17% | 10.6% |
Investors who own it
Investors we follow who held Personalis at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management0.7% of portfolioadded
More on Personalis
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .